Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial

被引：0
|
作者：
Beck, Lisa A. [1 ]
Deleuran, Mette [2 ]
Hong, H. Chih-Ho [3 ,4 ]
Adam, David N. [4 ,5 ,6 ]
Hussain, Iftikhar [7 ]
Zhang, Haixin [8 ]
Shabbir, Arsalan [8 ]
Rodriguez Marco, Ainara [9 ]
Levit, Noah A. [8 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY USA
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Univ British Columbia, Surrey, BC, Canada
[4] Canada Prob Med Res, Waterloo, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] CCA Med Res, Ajax, ON, Canada
[7] Vital Prospects Clin Res Inst PC, Tulsa, OK USA
[8] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[9] Sanofi Genzyme, Madrid, Spain
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
34385
引用
收藏
页码：AB206 / AB206
页数：1
相关论文
共 50 条
  • [41] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
    Blauvelt, Andrew
    Langley, Richard G.
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew E.
    Peris, Ketty
    Fangel, Stine
    Gjerum, Le
    Corriveau, Joshua
    Saeki, Hidehisa
    Warren, Richard B.
    Simpson, Eric
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
  • [42] SAFETY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Sierka, D.
    Coleman, A.
    Gherardi, G.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S92 - S92
  • [43] Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
    Blauvelt, Andrew
    Ladizinski, Barry
    Prajapati, Vimal H.
    Laquer, Vivian
    Fischer, Alison
    Eisman, Samantha
    Hu, Xiaofei
    Wu, Tianshuang
    Calimlim, Brian M.
    Kaplan, Blair
    Liu, Yingyi
    Teixeira, Henrique D.
    Liu, John
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 478 - 485
  • [44] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 67 - 68
  • [45] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 155 - 155
  • [46] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Deleuran, Mette
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Galus, Ryszard
    Nakahara, Takeshi
    Seo, Seong Jun
    Khokhar, Faisal A.
    Vakil, Jignesh
    Xiao, Jing
    Marco, Ainara Rodriguez
    Levit, Noah A.
    O'Malley, John T.
    Shabbir, Arsalan
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 393 - 408
  • [47] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Mette Deleuran
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Ryszard Galus
    Takeshi Nakahara
    Seong Jun Seo
    Faisal A. Khokhar
    Jignesh Vakil
    Jing Xiao
    Ainara Rodriguez Marco
    Noah A. Levit
    John T. O’Malley
    Arsalan Shabbir
    American Journal of Clinical Dermatology, 2022, 23 : 393 - 408
  • [48] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    Blauvelt, Andrew
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Hide, Michihiro
    Sher, Lawrence
    Hussain, Iftikhar
    Chen, Zhen
    Khokhar, Faisal A.
    Beazley, Bethany
    Ruddy, Marcella
    Patel, Naimish
    Graham, Neil M. H.
    Ardeleanu, Marius
    Shumel, Brad
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) : 567 - 577
  • [49] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Diamant Thaçi
    Mette Deleuran
    Andrew Blauvelt
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Michihiro Hide
    Lawrence Sher
    Iftikhar Hussain
    Zhen Chen
    Faisal A. Khokhar
    Bethany Beazley
    Marcella Ruddy
    Naimish Patel
    Neil M. H. Graham
    Marius Ardeleanu
    Brad Shumel
    American Journal of Clinical Dermatology, 2020, 21 : 567 - 577
  • [50] Safety efficacy of open-label dupilumab in adult patients with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE)
    Thaci, D.
    Deleuran, M.
    Bissonnette, R.
    Bouaziz, J. D.
    Sun, X.
    Patel, N.
    Shumel, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E94 - E94
12345